Last update 09 Dec 2024

Sulfamethoxazole

Last update 09 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummarySulfamethoxazole was first approved in 1965 by FDA , it was first marketed by Roche and sold under the trade name Gantanol® in the US. Sulfamethoxazole is used to treat bacterial infections such as urinary tract infections, bronchitis, and prostatitis. The drug works by binding to the dihydropteroate synthase (DHPS), an enzyme involved in bacterial folic acid synthesis. Sulfamethoxazole is known to cause side effects such as gastrointestinal disturbances (nausea, vomiting) and allergic skin reactions. It is now mostly used in combination with trimethoprim and as a first-choice treatment for urinary tract infections.

Drug Type

Small molecule drug

Synonyms

3-(p-Aminophenylsulfonamido)-5-methylisoxazole, 3-Sulfanilamido-5-methylisoxazole, 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide

+ [11]

Target

bacterial DHPS

Mechanism

bacterial DHPS inhibitors(Bacterial dihydropteroate synthase inhibitors)

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Urinary Tract Infections

Originator Organization

Hoffmann-La Roche, Inc.

Active Organization-

Inactive Organization

Hoffmann-La Roche, Inc.

Drug Highest PhaseApproved

First Approval Date

US (25 Aug 1965),

Urinary Tract Infections

Regulation-

Structure

Molecular FormulaC10H11N3O3S

InChIKeyJLKIGFTWXXRPMT-UHFFFAOYSA-N

CAS Registry723-46-6

Clinical Trials associated with Sulfamethoxazole

ChiCTR2100045333 / SuspendedNot Applicable

Prophylaxis of pneumocystis jiroveci infection after renal transplantation with very low dose of compound sulfamethoxazole dispersible tablets: a prospective randomized controlled study

Start Date01 Oct 2022

Sponsor / Collaborator-

TCTR20191025002 / Not yet recruitingPhase 3IIT

Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii Pneumonia prophylaxis in B-cell lymphoma patients receiving chemotherapy: A multicenter randomized double-blinded placebo-controlled trial

Start Date01 Dec 2019

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

[+1]

NCT02902640 / CompletedNot Applicable

A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Patients With Acute Bronchitis

This is a pilot, observational and multicentric study of safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in adult participants with acute bronchitis. Adult participants with acute bronchitis eligible for treatment with Balsamic Bactrim will be enrolled. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling.

Start Date15 Nov 2016

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Sulfamethoxazole

100 Translational Medicine associated with Sulfamethoxazole

100 Patents (Medical) associated with Sulfamethoxazole

12,104

Literatures (Medical) associated with Sulfamethoxazole

01 May 2025·Journal of Environmental Sciences

Efficient activation of peroxymonosulfate for catalytic degradation of organic pollutants by simultaneously using low-level cobalt ions and calcium carbonate micro-particles

Article

Author: Zhou, Yu ; Wang, Xiaobo ; Huang, Shuangshuang ; Wang, Nan ; Zhu, Lihua

An efficient catalytic system was developed to remove various organic pollutants by simultaneously using low-level cobalt ions, calcium carbonate micro-particles and peroxymonosulfate (PMS). A simple base-induced precipitation was used to successfully loaded Co-centered reactive sites onto the surface of CaCO₃ microparticles. Under optimal conditions at 25 °C, 10 mg/L methylene blue (MB) could be completely degraded within 10 min with 480 µg/L Co²⁺, 0.4 g/L CaCO₃ microparticles (or 0.4 g/L Co@CaCO₃) and 0.1 g/L PMS. The MB degradation followed the pseudo first order kinetics with a rate constant of 0.583 min^-1, being 8.3, 11.5 and 53.0 times that by using Co-OH (0.07 min^-1), Co²⁺ (0.044 min^-1) and CaCO₃ (0.011 min^-1) as the catalyst, respectively. It was confirmed that there was a synergistic effect in the catalytic activity between Co species and the CaCO₃ particles but the major contributor was the highly dispersed Co species. When Co²⁺-containing simulated electroplating wastewater was used as the Co²⁺ source, not only the added MB was also completely degraded within 5 min in this catalytic system, but also the coexisting heavy metal ions were substantially removed. The presently developed method was applied to simultaneously treat organic wastewater and heavy metals wastewater. The present method was also successfully used to efficiently degrade other organic pollutants including bisphenol A, sulfamethoxazole, rhodamine B, tetrabromobisphenol A, ofloxacin and benzoic acid. A catalytic mechanism was proposed for the PMS activation by Co@CaCO₃. The surface of CaCO₃ particles favors the adsorption of Co²⁺. More importantly, the surface of CaCO₃ particles provides plentiful surface -OH and -CO₃²⁺, and these surface groups complex with Co²⁺ to produce more catalytically active species such as surface [CoOH]^-, resulting in rapid Co²⁺/Co³⁺ cycling and electron transfer. These interactions cause the observed synergistic effect between Co species and CaCO₃ particles in PMS activation. Due to good cycle stability, strong anti-interference ability and wide universality, the new method will have broad application prospects.

01 Mar 2025·TALANTA

Voltammetric methodology for the quality control and monitoring of sulfamethoxazole removal from water

Article

Author: Sanromán, M Ángeles ; González-Romero, Elisa ; Pazos, Marta ; Bernárdez, Nuria ; Caruncho-Pérez, Sara

Sulfamethoxazole is an antibiotic that is among the drugs most frequently found in waters around the world because of its habitual consumption and its high chemical stability that prevents it from being eliminated from the environment. In this study, an electroanalytical methodology based on differential pulse voltammetry is developed for the analysis of sulfamethoxazole at trace levels in water. After the optimization of the instrumental parameters a linear range from 6.59 to 96.27 μM was found with limits of detection and quantification of 1.98 and 6.59 μM, respectively, with an RSD below 6 %. Moreover, several validation studies involving different pH values, water samples and instrumentation-techniques were performed in order to ensure the robustness of the method. For this purpose, the peak area was used as quantitative variable since it is not affected by the pH of the medium even if there is any modification of this parameter during the experiments. Furthermore, the effect of other drug such as trimethoprim on the analytical signal of sulfamethoxazole was also evaluated. Once the method was developed it was tested on the quality control of Soltrim®, obtaining recoveries between 98 and 102 %. Lastly, the voltammetric method was applied for the in situ monitoring of sulfamethoxazole's removal from water samples, specifically by anodic oxidation and electro-Fenton treatments. While the former was coupled to an adsorption process, the latter was carried out with different iron sources including commercial medicines that can be found in wastewater. The problem of significant variation in pH during the treatment was solved by working with the peak area, and so obtaining valid and reliable kinetic data. Although anodic oxidation proved to be faster considering the calculated k_obs, electro-Fenton turned out to be more efficient in eliminating the drug, achieving the disappearance of its analytical signal in only 30 min of treatment.

01 Feb 2025·JOURNAL OF HAZARDOUS MATERIALS

Selected emerging contaminants in water: Global occurrence, existing treatment technologies, regulations and associated risk

Review

Author: Swami, Deepak ; Prasher, Shiv O ; Chandel, Aman ; Joshi, Nitin ; Meena, Vinay

Emerging contaminants (ECs) in aquatic environments have recently attracted the attention of researchers due to their ubiquitous occurrence and the potential risk they may pose to life. While advance analytical methods have improved global reporting in water matrices, additional information is needed to compile data on their occurrence, existing legislation, treatment technologies and associated human health risks. Therefore, the present study provides an overview of the occurrence of selected ECs, including personal care product, antibiotics, NSAIDs, EDCs and psychiatric drugs, the existing regulatory framework and their toxicological effects on human health. The water matrices under review are the treated wastewater, surface water, groundwater and, in a few cases, drinking water. The study also highlights different treatment technologies available, and evaluates their performance based on the removal efficiency for different classes of ECs. For removal of almost all ECs considered, ozonation integrated with gamma radiation was reported highly efficient. Risk analysis was also performed for selected ECs including diclofenac, ibuprofen, naproxen, carbamazepine, estrone, 17 β-estradiol, bisphenol A, sulfamethoxazole, erythromycin and triclosan. The human health risk analysis indicated the highest number of locations with potential risk due to the EDCs, with South America, Europe and Asia having multiple risks due to estrone and Bisphenol A. The results of this study will give a better insight into the current situation of ECs in the global water matrices, the performance assessment of treatment technologies and the risk analysis will describe the need for more robust regulatory structures around the world to prevent the occurrence of such contaminants in the aquatic environment.

News (Medical) associated with Sulfamethoxazole

12 Aug 2024

·www.globenewswire.com

Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases

Primary and secondary objectives were met in the open-label randomized Part 1 of the clinical trial to treat uncomplicated UTIs caused by antibiotic-resistant E. coli Dosing has begun in Part 2, the controlled, double-blind portion of the trial triggered by the success in Part 1 Data support potential of Locus’ engineered bacteriophage platform in combatting the global health crisis of infections caused by multidrug-resistant (MDR) pathogens RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial. This Phase 2 trial is evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli). Data from the randomized, uncontrolled, open-label Part 1 portion of the trial were published in The Lancet Infectious Diseases. Locus also announced that dosing has begun in the randomized, controlled, and blinded Part 2 portion of this Phase 2 study. This clinical trial is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Worldwide, an estimated 150 million people are affected by UTIs each year. Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics. Up to 40% of UTI patients experience a recurrence, often within months of the first episode. Both the U.S. Centers for Disease Control and Prevention and the World Health Organization have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring the development of new treatments. Part 1 of ELIMINATE enrolled 39 adult female patients, across six United States-based clinical centers and had an overall objective of defining a dosing regimen of LBP-EC01 and oral trimethoprim/sulfamethoxazole (TMP/SMX) to advance to Part 2 of the trial. This overall objective was supported by analysis of the primary outcome of pharmacokinetics (PK) in urine and blood, and the secondary outcome of safety, which were assessed on randomized patients dosed at least once with LBP-EC01. In addition, an exploratory outcome of pharmacodynamic (PD) assessments was performed on 16 evaluable patients. “The need for new targeted antibacterial therapies is urgent given the increasing impact of antibiotic-resistant pathogens, which we see in our clinic every day,” said Juvenal E. Martinez, M.D., an investigator in the trial. “As the first Phase 2 engineered bacteriophage trial, ELIMINATE is breaking new ground in the quest to address increasingly prevalent serious MDR infections. This encouraging initial data support the possible utility of bacteriophages and the potential of LBP-EC01 as a therapeutic option to address drug-resistant bacterial infections, such as UTIs, which have a high recurrence rate due to MDR pathogens.” ELIMINATE Trial Part 1 Results The primary and secondary outcomes of Part 1 were met, and a dosing regimen was identified that was well-tolerated and which led to high drug exposure at the site of infection. No serious adverse events were observed in Part 1, and exposure to LBP-EC01 did not lead to any observations of genetic resistance in any subsequently recovered E. coli samples. Part 1 was initiated with three treatment groups focused on intravenous (IV) delivery of a high 1×1011 plaque forming units (PFU)/dose of LBP-EC01 which was halted after three patients discontinued dosing due to non-serious adverse events of mild tachycardia and afebrile chills. Three updated treatment groups, which focused on a short, 3-day course of intra-urethral (i.e., IU or direct to bladder) and lower exposure IV dosing, replaced the original treatment groups. With this updated dosing approach, a rapid reduction of E. coli in urine was observed four hours after the first treatment which was maintained to the day 10 test of cure (TOC) evaluation. All (16 of 16) patients in the evaluable population had complete resolution of UTI symptoms and 14 of 16 (87.5%) patients demonstrated microbiologic cure or reduction of their bacterial infection below 1×103 colony forming units (CFU)/mL in urine by the day 10 TOC. A dosing regimen of LBP-EC01 given for 2 days IU (2×1012 PFU/dose) and given concurrently for 3 days IV (1×1010 PFU/dose) with concomitant oral TMP/SMX (160 mg TMP/800 mg SMX twice daily) has been advanced into Part 2. ELIMINATE Trial Part 2 underway Part 2 of the ELIMINATE trial has been initiated with patient dosing underway. This randomized, controlled, double-blind portion of the trial will evaluate the efficacy, safety, tolerability, and pharmacokinetics of LBP-EC01 with TMP/SMX. Up to 288 female uncomplicated UTI patients will be enrolled and randomized in a 1:1 ratio where patients will receive LBP-EC01 or placebo for the 3-day dosing regimen selected from Part 1. The primary objective will be to evaluate the effect of LBP-EC01 given with TMP/SMX on its ability to treat acute UTIs in patients with a history of UTI recurrence. The impact of the treatment on reducing UTI recurrence and/or extending the duration of time to the next UTI recurrence will be examined as an exploratory endpoint in a 6-month follow-up evaluation. This trial is registered with ClinicalTrials.gov, NCT05488340, and is ongoing. “These milestones represent a huge step forward in the critical fight against MDR. Over the past eight years, we have invested significant resources to build the Locus engineered bacteriophage platform. We developed our high-throughput robotics and AI technology to optimize a fixed set of precisely engineered phages that target over 95 percent of current uropathogenic E. coli strains, including MDR strains. We also built a world-class viral vector manufacturing facility that produces GMP materials at potency and purity levels higher than any others we have seen in the field to date. These Part 1 data validate our platform and support the advancement of a potential first-in-class therapy,” said Paul Garofolo, Co-founder and CEO of Locus. “We are grateful for the participating sites, clinicians, and patients, and our funding partner BARDA. We are eager to build on this positive momentum as we continue Part 2 of the ELIMINATE trial.” For more information on Part 1 of the ELIMINATE trial, visit clinicaltrials.gov using the identifier NCT05488340. Patients interested in participating in Part 2 can visit www.eliminateuti.com. About LBP-EC01LBP-EC01 is a CRISPR-enhanced bacteriophage therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen E. coli. It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR-Cas3. LBP-EC01 previously met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase 1b trial. LBP-EC01 is currently being evaluated in a Phase 2 trial for the treatment of UTIs caused by E. coli. In 2020, Locus and BARDA, part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), announced an agreement to co-fund development of LBP-EC01. Under the partnership agreement, contract number 75A50120C00169, BARDA will provide up to $93 million to Locus as part of a $152 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01. About Locus BiosciencesLocus Biosciences is creating a new class of precision biotherapeutics with clinical-stage engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases. A world-leading bacteriophage discovery, synthetic biology, and manufacturing platform powers the company. Locus engineers bacteriophage - naturally occurring viruses that target bacteria - to kill pathogenic bacteria, while sparing good bacteria, through programmable precision anti-bacterials with CRISPR-Cas3 and other therapeutic payloads. Its artificial intelligence and machine-learning based discovery engine targets bacteria that are associated with disease across multiple therapeutic areas including infectious disease, immunology, and oncology. Locus has secured multiple non-dilutive partnerships to support development of the company’s platform and programs. These include anti-bacterial partnerships with Biomedical Advanced Research and Development Authority (BARDA) for its lead asset targeting E. coli and Combatting Antibiotic Resistant Bacteria Accelerator (CARB-X) for its asset targeting K. pneumoniae. For more on the Research Triangle Park, N.C.-based company, visit www.locus-bio.com. Media Contact:Gina Mangiaracina6 Degrees gmangiaracina@6degreespr.com

Clinical ResultPhase 2License out/inPhase 1

08 Jul 2024

·www.prnewswire.com

When Our Genes Make Us Sick From Medication

New research is uncovering genetic predispositions to developing DRESS Syndrome RICHMOND, Va., July 8, 2024 /PRNewswire/ -- In honor of National DRESS Syndrome Day, July 16, the DRESS Syndrome Foundation is raising awareness about genetic predispositions to developing severe cutaneous adverse drug reactions (SCARs) like DRESS Syndrome. DRESS is a life-threatening condition that results from taking medications, most commonly antibiotics and anticonvulsants. Researchers are working to reveal the link between our genes and these drugs. The goal is to more effectively treat — and prevent — DRESS Syndrome. Continue Reading National DRESS Syndrome Day 2024 Tasha Tolliver, Executive Director DRESS Syndrome Foundation Dr. Elizabeth Phillips, Vanderbilt University Medical Center "Worldwide, patients are often prescribed medications without a full understanding as to whether these drugs are safe for them to take," explains Tasha Tolliver, Executive Director of the DRESS Syndrome Foundation. "We're thankful that a global team of dedicated researchers is identifying genetic markers that make people susceptible to developing severe drug reactions. This will be a huge step forward in preventing DRESS Syndrome while helping to manage risk and prevent harm." To date, the medical community has discovered that select drugs carry genetic risk factors for getting DRESS Syndrome and other SCARs. The prevalence of individual genes can vary, depending on the population, like Asian, European, Thai, etc. When patients carry a genetic risk, they have a greater chance of developing DRESS or another SCAR from that specific medication. Dr. Elizabeth Phillips is a globally renowned severe drug reaction researcher at Vanderbilt University Medical Center. She and her team are uncovering genetic markers that can predict a patient's likelihood for developing SCARs. They recently discovered that the gene HLA-A*32:01 can increase a person's chance for developing DRESS from the commonly prescribed antibiotic Vancomycin. Dr. Phillips and her team have also developed genetic tests for Vancomycin. Although relatively cheap and easy to do, the tests are not yet widely implemented. With more widespread use, medical providers could prevent and better diagnose DRESS Syndrome cases. Before prescribing a medication like Vancomycin, they could weigh the benefit of receiving it against someone's drug reaction risk. "We are entering an era where these decision support tools can be a tremendous help," says Dr. Phillips. "However, clinical practice is still behind in implementing these tests effectively in pharmacogenomics education. In this rapidly changing field, it is crucial to help doctors, nurses, and pharmacists understand and make decisions." Dr. Phillips suggests that to better prevent and manage SCARs, general medical board certification and CME requirements should also require pharmacogenetics knowledge. National DRESS Syndrome Day takes place each year on July 16. The 2024 theme is "Voices for DRESS." Among other actions, they will recognize medical professionals as "DRESS Heroes" and invite patients and medical experts to share their personal DRESS experiences. What Is DRESS Syndrome ? DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms A severe, cutaneous adverse reaction to medication. Symptoms are delayed (2 – 8 weeks) and can occur from taking one of over 50 prescription drugs like antibiotics and anticonvulsants. Five prescription drugs account for over 50% of cases and 56% of reported deaths: Allopurinol, Carbamazepine, Lamotrigine, Sulfamethoxazole/Trimethoprim (Bactrim) and Vancomycin. One in every 1,000 to 10,000 drug exposures will result in DRESS. 10% of people with DRESS will die. DRESS usually begins with rash, fever, lymphadenopathy, and facial swelling; and leads to blood abnormalities and organ injury, typically of the liver, kidneys, lungs, and heart. It can result in long-term autoimmune complications. About The DRESS Syndrome Foundation The DRESS Syndrome Foundation is a 501(c)(3) nonprofit based in Richmond, Virginia. We are a collaborative network of patients, families, researchers, and physicians dedicated to educating about severe adverse drug reactions, while advocating for the advancement of research, treatments, and prevention. We serve patients and their loved ones worldwide. Learn more at: DRESSsyndromefoundation.org Contact: Deanna Lorianni Communications Director DRESS Syndrome Foundation 804.307.6703 [email protected] SOURCE DRESS Syndrome Foundation

23 Jan 2024

·www.biospace.com

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

ELIMINATE trial is evaluating LBP-EC01 for treating urinary tract infections caused by drug-resistant E. coli Funding to support advancement into Part 2 of ELIMINATE trial RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial. Worldwide, an estimated 150 million people are affected by UTIs each year. Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics. Up to 40% of UTI patients experience a recurrence, often within months of the first episode. Both the U.S. Centers for Disease Control and Prevention and the World Health Organization have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring development of new treatments. “Engineered bacteriophage have emerged as one of the most promising technologies for addressing the worldwide public health crisis of multi-drug resistant (MDR) bacterial infections. While multiple small-scale studies have shown promise, the field urgently needs a definitive large-scale placebo-controlled study to conclusively test the efficacy of an engineered bacteriophage therapy,” said Paul Garofolo, Co-founder and CEO of Locus. “We are incredibly grateful for our partnership with BARDA in funding this clinical trial of a potential first-in-class precision medicine for an important unmet medical need.” The company’s recent successful completion of the uncontrolled open-label Part 1 portion of the two-part ELIMINATE Phase 2 trial triggered the release of this tranche of funding under its $85 million contract (75A50120C00169) with BARDA. The funding will be used to advance LBP-EC01 into the blinded, placebo-controlled, Part 2 of the ELIMINATE Phase 2 trial. In 2020, Locus and BARDA announced an agreement to co-fund development of LBP-EC01. Under the contract, BARDA will provide up to $85 million in funding to Locus as part of a $152 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration for LBP-EC01. The award announced today brings the amount released under the contract to $48.9 million. About the ELIMINATE Trial The two-part multicenter Phase 2 ELIMINATE trial is evaluating LBP-EC01 used concomitantly with trimethoprim/sulfamethoxazole (TMP/SMX) in adult female patients for the treatment of uncomplicated UTIs caused by drug resistant E. coli. The uncontrolled open-label Part 1 (dose-regimen selection) evaluated the safety, tolerability, pharmacokinetics and clinical and microbiologic outcomes of LBP-EC01 and TMP/SMX in 39 patients with uncomplicated UTI. Part 2 of the study has a primary objective of determining the efficacy of LBP-EC01 when used concomitantly with TMP/SMX, compared to control (placebo plus TMP/SMX), based on combined clinical and microbiological response of acute uUTI caused by drug resistant E. coli in up to 288 adult female patients. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120C00169. For more information, visit clinicaltrials.gov using the identifier NCT05488340. Patients interested in participating in Part 2 of the Phase 2 trial can visit . About LBP-EC01 LBP-EC01 is a CRISPR-enhanced bacteriophage therapy in development for the treatment of urinary tract infections and other infections caused by the bacterial pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR. LBP-EC01 previously met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase 1b trial. LBP-EC01 is currently being evaluated in a Phase 2 trial for the treatment of UTIs caused by E. coli. About Locus Biosciences Locus Biosciences is creating a new class of precision biotherapeutics with clinical-stage engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases. A world-leading bacteriophage discovery, synthetic biology, and manufacturing platform powers the company. Locus engineers bacteriophage - naturally occurring viruses that target bacteria - to kill pathogenic bacteria, while sparing good bacteria, through programmable precision anti-bacterials with CRISPR-Cas3 and other therapeutic payloads. Its artificial intelligence and machine-learning based discovery engine targets bacteria that are associated with disease across therapeutic areas including infectious disease, immunology, and oncology. Locus has secured multiple non-dilutive partnerships to support development of the company’s platform and programs. These include contracts with Biomedical Advanced Research and Development Authority (BARDA) for Locus’ lead asset targeting E. coli and Combatting Antibiotic Resistant Bacteria Accelerator (CARB-X) for Locus’ asset targeting K. pneumoniae. For more on the Research Triangle Park, N.C.-based company, visit . Media Contact: Heather Anderson 6 Degrees handerson@6degreespr.com

Phase 2Phase 1Clinical Result

100 Deals associated with Sulfamethoxazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00447	Sulfamethoxazole	J01EC01	DB01015

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Urinary Tract Infections	US	Hoffmann-La Roche, Inc.	25 Aug 1965

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Am J Trop Med Hyg	Not Applicable	HIV Infections	70	Sulfamethoxazole (HIV-Exposed Uninfected (HUE) children)	lspmbquonb(ulswrjfazs) = rxondpcltx crhhocnotz (dmfrrcjmbn )	-	01 Jun 2018
ASN2016	Not Applicable	Kidney Diseases \| Acute Kidney Injury \| HIV Infections	-	Trimethoprim-Sulfamethoxazole (TMP-SMX)	uoafopjmyb(wyqplvzbly) = qfqhtlbmwe wfgjdyldow (lvzywibiiq ) View more	-	15 Nov 2016
AAAAI2013	Not Applicable	Systemic Lupus Erythematosus anti-Ro/SS-A antibody	31	TMP/SMX	stmzxqskua(frepdvbuxz) = lxyffzynuq wlkssrzhgg (ofajpeqbrf )	Positive	01 Feb 2013
NCT00014911 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	36	Islet Transplantation+Ganciclovir+Sulfamethoxazole+Tacrolimus+Sirolimus+Daclizumab+Pentamidine+Trimethoprim	ujqwspjdpa(qnnobngrxw) = rqcjkoznbd aoahczcbgy (idsmdruvrw, aiylsrxzeh - jaiqxfrevl) View more	-	17 Oct 2012
ASN2011	Not Applicable	-	10	Sulfamethoxazole (HF1000 polysulfone hemofilter)	gcpoehqbze(ekpdlgrova) = jynrebjpxz hrtoiqygcx (khpqswdvab )	Positive	08 Nov 2011
ASN2011	Not Applicable	-	10	Sulfamethoxazole (M100 AN69 hemofilter)	gcpoehqbze(ekpdlgrova) = lgzmgtywdi hrtoiqygcx (khpqswdvab )	Positive	08 Nov 2011
AAAAI2007	Not Applicable	Acquired Immunodeficiency Syndrome	6	Sulfa (HIV/AIDS patients)	(zjqwmlkvjj) = 5/6 developed cutaneous burning sensation followed by generalized maculopapular rash with a median onset after the last dose of 12 hours. Only antihistamines were used. The symptoms resolved within 6 days (median of 2 days, range 1-6 days) rcacwxgbil (yqajnczsfi )	-	01 Jan 2007

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis